Stocktoria
Insight Molecular Diagnostics Inc. IMDX
Insight Molecular Diagnostics Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M | $1.2M | — | — | — | — |
| Gross profit | $2.3M | $740,000 | $413,000 | -$18,000 | $1.4M | -$639,000 | — | — | — | — |
| R&D expense | $15.9M | $9.8M | $9.3M | $7.3M | $5.0M | $9.8M | $6.8M | $6.5M | $7.2M | $5.7M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M | -$29.7M | -$22.2M | -$15.2M | -$18.8M | -$11.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | $0 |
| Income tax | $0 | $0 | $0 | — | -$9.3M | -$1.3M | — | — | — | — |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | -$64.1M | -$29.9M | -$22.4M | -$15.8M | -$19.4M | -$11.2M |
| EPS (diluted) | $-1.65 | $-4.66 | $-3.75 | $-13.25 | — | — | — | — | — | — |
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M | -$26.0M | -$19.7M | -$11.6M | -$13.4M | -$7.5M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M | -$27.2M | -$20.6M | -$11.7M | -$13.5M | -$7.6M |
| Cash & equivalents | $11.6M | $8.6M | $9.4M | $20.0M | $32.9M | $7.1M | $22.1M | $8.0M | $7.6M | $10.2M |
| Inventory | $446,000 | $410,000 | — | — | — | — | — | — | — | — |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M | $55.4M | $39.9M | $9.5M | $10.2M | $14.4M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M | $21.9M | $9.0M | $6.1M | $5.8M | $4.6M |
| Shareholders' equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M | $33.5M | $30.8M | $3.4M | $4.4M | $9.9M |
Growth · year-over-year · Revenue CAGR 27.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +115.6% | +25.1% | +56.9% | -56.4% | +80.8% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.